论文部分内容阅读
目的:探讨托拉塞米治疗终末期肥厚型非梗阻性心肌病的临床疗效和安全性。方法:对52例终末期肥厚型非梗阻性心肌病患者用托拉塞米(托拉塞米组)和呋噻米(对照组)治疗10d。将体重、水肿程度、心功能分级、B型钠尿肽、血管紧张素Ⅱ、血钾、血钠、血氯含量等作为评价指标。结果:治疗10d后,托拉塞米组和对照组的心功能有显著改善,两组比较差异有统计学意义(P<0.01)。两组治疗前后的血钾、血钠、血氯等指标无明显变化。托拉塞米组和对照组的不良反应发生率分别为14.8%和24.0%,两组比较差异有统计学意义(P<0.01)。结论:每天1次静脉注射托拉塞米40mg治疗终末期肥厚型非梗阻性心肌病患者,能够显著改善心脏功能,效果明显优于呋噻米,且安全性较高。
Objective: To investigate the clinical efficacy and safety of torsemide in the treatment of end-stage hypertrophic non-obstructive cardiomyopathy. Methods: 52 patients with end-stage hypertrophic non-obstructive cardiomyopathy were treated with torsemide (torsemide) and furosemide (control group) for 10 days. Body weight, edema, heart function grading, B-type natriuretic peptide, angiotensin Ⅱ, serum potassium, serum sodium, blood chlorine content as the evaluation index. Results: After 10 days of treatment, the heart function of torsemide group and control group were significantly improved, with significant difference between the two groups (P <0.01). Before and after treatment of serum potassium, serum sodium, blood chlorine and other indicators no significant change. The rates of adverse reactions in torasemide group and control group were 14.8% and 24.0%, respectively, with significant difference between the two groups (P <0.01). CONCLUSIONS: Intravenous injection of torsemide 40 mg daily in patients with end-stage hypertrophic non-obstructive cardiomyopathy can significantly improve cardiac function, with significantly better efficacy than furosemide and higher safety.